HLS THERAPEUTICS INC (HLS.CA) Stock Price, Forecast & Analysis
Canada - TSX:HLS - CA40390B1094 - Common Stock
HLS.CA Key Statistics, Chart & Performance
The current stock price of HLS.CA is 4.95 CAD. In the past month the price decreased by -11.61%. In the past year, price increased by 54.69%.
HLS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.65 | 3.26B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.71B | ||
| CRON.CA | CRONOS GROUP INC | 24.64 | 1.32B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.39 | 885.25M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 122.8 | 612.04M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 510.76M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 339.75M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 20.55 | 332.96M | ||
| HITI.CA | HIGH TIDE INC | N/A | 331.47M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 283.44M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 244.46M | ||
| XLY.CA | AUXLY CANNABIS GROUP INC | 4 | 215.72M |
Related stock screener links
About HLS.CA
Company Profile
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Company Info
HLS THERAPEUTICS INC
10 Carlson Court, Suite 701
Etobicoke ONTARIO M9W 6L2 CA
CEO: Christopher Nutt
Employees: 92
Phone: 16474959000
HLS THERAPEUTICS INC / HLS.CA FAQ
Can you describe the business of HLS THERAPEUTICS INC?
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Can you provide the latest stock price for HLS THERAPEUTICS INC?
The current stock price of HLS.CA is 4.95 CAD. The price increased by 4.21% in the last trading session.
Does HLS stock pay dividends?
HLS.CA does not pay a dividend.
How is the ChartMill rating for HLS THERAPEUTICS INC?
HLS.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ex-dividend date for HLS stock?
The next ex-dividend date for HLS THERAPEUTICS INC (HLS.CA) is April 27, 2023.
How many employees does HLS THERAPEUTICS INC have?
HLS THERAPEUTICS INC (HLS.CA) currently has 92 employees.
What is HLS THERAPEUTICS INC worth?
HLS THERAPEUTICS INC (HLS.CA) has a market capitalization of 154.84M CAD. This makes HLS.CA a Micro Cap stock.
HLS.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HLS.CA. When comparing the yearly performance of all stocks, HLS.CA is one of the better performing stocks in the market, outperforming 74.57% of all stocks.
HLS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA. HLS.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
HLS.CA Financial Highlights
Over the last trailing twelve months HLS.CA reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.09% | ||
| ROE | -22.6% | ||
| Debt/Equity | 0.74 |
HLS.CA Forecast & Estimates
9 analysts have analysed HLS.CA and the average price target is 6.83 CAD. This implies a price increase of 38.06% is expected in the next year compared to the current price of 4.95.
For the next year, analysts expect an EPS growth of 47.87% and a revenue growth 0.81% for HLS.CA